ஹாரி கரேலிஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Zelira Therapeutics well positioned for multiple product launches in 2021 Zelira Therapeutics Ltd s (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) Harry Karelis and Dr Oludare Odumosu speak to Proactive s Andrew Scott soon after announcing record product sales and licensing revenues of A$225,000 during the March quarter - up 249% on the prior six months. They say the revenue growth demonstrates the start of the company’s commercialisation ramp-up, with growth driven largely by the successful December 2020 launch of the Sprinjene CBD oral care product in the USA. Quick facts: Zelira Therapeutics Ltd Price: 0.06 AUD

United statesG harry karelisOludare odumosuAndrew scottZelira therapeutics ltdHarry karelisSmall capsTc markets quotedOtcqb quotedDirector interviewsZelira therapeutics ltdSx zldஒன்றுபட்டது மாநிலங்களில்ஆண்ட்ரூ ஸ்காட்ஹாரி கரேலிஸ்சிறிய தொப்பிகள்